Author:
Tarride JE,Okoh A.,Aryal K.,Prada C.,Milinkovic Deborah,Keepanasseril A.,Iorio A.
Abstract
Abstract
Background
Rare disease registries (RDRs) are valuable tools for improving clinical care and advancing research. However, they often vary qualitatively, structurally, and operationally in ways that can determine their potential utility as a source of evidence to support decision-making regarding the approval and funding of new treatments for rare diseases.
Objectives
The goal of this research project was to review the literature on rare disease registries and identify best practices to improve the quality of RDRs.
Methods
In this scoping review, we searched MEDLINE and EMBASE as well as the websites of regulatory bodies and health technology assessment agencies from 2010 to April 2023 for literature offering guidance or recommendations to ensure, improve, or maintain quality RDRs.
Results
The search yielded 1,175 unique references, of which 64 met the inclusion criteria. The characteristics of RDRs deemed to be relevant to their quality align with three main domains and several sub-domains considered to be best practices for quality RDRs: (1) governance (registry purpose and description; governance structure; stakeholder engagement; sustainability; ethics/legal/privacy; data governance; documentation; and training and support); (2) data (standardized disease classification; common data elements; data dictionary; data collection; data quality and assurance; and data analysis and reporting); and (3) information technology (IT) infrastructure (physical and virtual infrastructure; and software infrastructure guided by FAIR principles (Findability; Accessibility; Interoperability; and Reusability).
Conclusions
Although RDRs face numerous challenges due to their small and dispersed populations, RDRs can generate quality data to support healthcare decision-making through the use of standards and principles on strong governance, quality data practices, and IT infrastructure.
Funder
Canadian Agency for Drugs and Technologies in Health (CADTH).
Publisher
Springer Science and Business Media LLC
Reference96 articles.
1. Canada’s Drug and Health Technology Agency (CADTH): Ahead of the Curve: Shaping Future-Ready Health System. (2022). https://strategicplan.cadth.ca/wp-content/uploads/2022/03/cadth_2022_2025_strategic_plan.pdf. Accessed March 15, 2023.
2. National Institute for Health and Care Excellence (NICE): NICE strategy 2021 to 2026 - Dynamic, Collaborative, Excellent. (2021). https://static.nice.org.uk/NICE%20strategy%202021%20to%202026%20-%20Dynamic,%20Collaborative,%20Excellent.pdf. Accessed March 15, 2023.
3. Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA, et al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021;372:m4856. https://doi.org/10.1136/bmj.m4856.
4. ISPOR: New Real-World Evidence Registry Launches. (2021). https://www.ispor.org/heor-resources/news-top/news/view/2021/10/26/new-real-world-evidence-registry-launches. Accessed March 15, 2023.
5. Corrigan-Curay J, Sacks L, Woodcock J. JAMA. 2018;320(9):867–8. https://doi.org/10.1001/jama.2018.10136. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.